References
- Simon V, Czobor P, Bálint S, et al. Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta-analysis. Br J Psychiatry. 2009;194(3):204–211.
- Faraone SV, Biederman J. What is the prevalence of adult ADHD? Results of a population screen of 996 adults. J Attention Disord. 2005;9:384–391.
- Wilens, Adler, Adams, et al. Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature. JACAAP 2008 Jan. 47(1):21–31
- Compton WM, Han B, Blanco C, et al. Prevalence and correlates of prescription stimulant use, misuse, use disorders, and motivations for misuse among adults in the United States. Am J Psychiatry. 2018 April;175:741–755.
- McCabe SE, West BT. Medical and non medical use of prescription stimulants: results from a national multicohort study. JAACAP. 2013 Dec;52(12):1272-1280.
- Jasinski FD, Allen AJ. Abuse liability assessment of atomoxetine in a drug abusing population.Drug and Alcohol Dependence 2008 May 1;95 (1-2):140-6
- Michelson, Allen,Casat, et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled. AJP. Nov 2002 159 (11):1896-901.
- DeLorenzo C, Lichenstein S, Schaefer K, et al. SEP-225289 serotonin and dopamine transporter occupancy: a PET study. J Nucl Med. 2011;52:1150–1155.
- Hannestad J, Gallezot JD, Planeta-Wilson B, et al. Clinically relevant doses of methylphenidate significantly occupy norepinephrine transporters in humans in vivo. Biol Psychiatry. 2010;68:854–860.
- Koblan KS, Hopkins SC, Sarma K, et al. Dasotraline for the treatment of ADHD: a randomized double blind placebo controlled proof of concept trial in adults. Neuropharmacology. 2015;40:2745–2752.
- Hopkins SC, Sunkaraneni S, Skende E, et al. Pharmacokinetics and exposure response relationships of dasotraline in the treatment of attention deficit hyperactivity disorder in adults. Clin Drug Investig. 2016;36:137–146.
- Faraone and Glat. A comparison of the efficacy of medications for adult ADHD using meta-analysis of effect size. J Clin Psychiatry. 2010 June;71:6.
- Faraone SV, Spencer T, Aleardi M, et al. Meta-analysis of the efficacy of methylphenidate for treating adult attention deficit /hyperactivity disorder. J Clin Pharmacol. 2004;24:24–26.
- Drug information face sheet for Aptensio XR. Available from 2018 Nov 21: www.accessdata.fda.gov/drugsatfda_docs/label/2017/205831s003lbl.pdf
- Drug information fact sheet for Adderall XR. Available from 2018 Nov 21: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021303s015lbl.pdf
- Drug information fact sheet for Lisdexamphetamine. Available from 2018 Oct 16: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021977lbl.pdf
- Spencer TJ, Biederman J, Martin JM, et al. Importance of pharmacokinetic profile and timing of co administration of short- and long-acting formulations of methylphenidate on patterns of subjective responses and abuse potential. Postgrad Med. 2012;124:166–173.
- Dasotraline efficacy throughout the day in children with ADHD: Results of a phase 3, randomized, double blind, placebo controlled study in a laboratory classroom setting
- Dasotraline in Children with ADHD: Results of a randomized, double blind, placebo controlled study. Robert Goldman, Lenard Adler, Thomas Spencer, Robert Findling et al Jaccap 2017. 09.361
- Dasotraline FDA approval status. Available from 2018 Nov 21: www.drugs.com/history/dasotraline.html
- Koblan, Hopkins, Galina, et al. Assessment of human abuse potential of dasotraline compared to methylphenidate and placebo in recreational stimulant users. Drug Alcohol Depend. 2016;159:26–34.
- Diaz-Roman A, Mitchell R, Cortese S. Sleep in adults with ADHD: systematic review and meta-analysis of subjective and objective studies. Neurosci Biobehav Rev. 2018;89:61–71.